[LIVER] Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients. https://t.co/0gjvY1S5w3
RT @CochraneKidney: Benefits of MMF must be weighed against potential harms eg tissue-invasive CMV disease after #kidney transplantation ht…
RT @CochraneKidney: MMF more effective than AZA for reducing the risk of graft loss and acute rejection after #kidney transplantation https…
RT @CochraneKidney: MMF more effective than AZA for reducing the risk of graft loss and acute rejection after #kidney transplantation https…
RT @CochraneKidney: MMF more effective than AZA for reducing the risk of graft loss and acute rejection after #kidney transplantation https…
RT @CochraneKidney: Benefits of MMF must be weighed against potential harms eg tissue-invasive CMV disease after #kidney transplantation ht…
Benefits of MMF must be weighed against potential harms eg tissue-invasive CMV disease after #kidney transplantation https://t.co/XR6w14vNPW
MMF more effective than AZA for reducing the risk of graft loss and acute rejection after #kidney transplantation https://t.co/XR6w14vNPW
Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant… https://t.co/fep5xF7FdF